Glenn Chertow

Glenn Chertow, MD, MPH, Professor, Department of Medicine, Division of Nephrology; Professor (by courtesy), Department of Epidemiology and Population Health, Stanford University School of Medicine

Research Description: Dr. Chertow is a heralded clinical investigator with a productive research program focused on improving care for persons with acute and chronic kidney disease (CKD) especially in the setting of diabetes. His research interests include clinical epidemiology, health-services research, decision sciences and clinical trials in acute and chronic kidney disease. Dr. Chertow has served or is currently serving in leadership roles for NIDDK, NHLBI, and VA-sponsored cohort studies and clinical trials, including HEMO, CRIC, DAC, HFMC, ATN, FHN, SPRINT, PRESERVE, ISCHEMIA, CURE-GN and TiME, and for several industry- sponsored clinical trials including TREAT, EVOLVE, BEACON and SYMPLICITY. Dr. Chertow served on the Data Safety and Monitoring Board for a series of dapaglaflozin clinical trials, and for several other clinical trials of investigational drugs for diabetes and diabetic kidney disease. Dr. Chertow was elected to the Association of American Physicians and to the National Academy of Medicine in 2015. He has also trained and mentored scientists and members of SDRC, including Drs. J. Rhee, T. Chang and V. Bhalla.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Ziolkowski SL, Long J, Baker JF, Chertow GM, Leonard MB. Relative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity. J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):338-346. doi: 10.1002/jcsm.12396. PMID: 30784237; PMCID: PMC6463461. 

  2. McCoy IE, Han J, Montez-Rath ME, Chertow GM, Rhee JJ. Patient and Provider Characteristics Associated With Sodium-Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. Clin Diabetes. 2020 Jul;38(3):240-247. doi: 10.2337/cd19-0087. PMID: 32699472; PMCID: PMC7364452. 

  3. Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:46-54. doi: 10.1111/dom.13987. PMID: 32267076. 

  4. Ziolkowski SL, Long J, Baker JF, Chertow GM, Leonard MB. Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded? J Ren Nutr. 2019 Nov;29(6):521-528. doi: 10.1053/j.jrn.2018.11.011. PMID: 30709713; PMCID: PMC6663655. 

  5. Rhee JJ, Han J, Montez-Rath ME, Kim SH, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM. Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. J Diabetes Complications. 2019 Nov;33(11):107423. doi: 10.1016/j.jdiacomp.2019.107423. PMID: 31537413; PMCID: PMC6823164.